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Abstract
Background: Posttraumatic stress disorder (PTSD) is a severe psychiatric disease accompanied by neuroendocrine
changes such as adrenergic overdrive and hence an elevated cardiovascular morbidity. Current pharmacotherapeutic
options for PTSD are less than suboptimal, necessitating the development of PTSD-specific drugs. Although the
neuropeptide oxytocin has been repeatedly suggested to be effective in PTSD treatment, there are, to our knowledge,
only three studies that have assessed its efficacy on the intensity of PTSD symptoms in PTSD patients – among them
one symptom provocation study in male veterans.
Methods: To evaluate for the first time how oxytocin influences the intensity of provoked PTSD symptoms and,
furthermore, cardiac control in female PTSD patients, we assessed their psychic and cardiac response to trauma-script
exposure with and without oxytocin pretreatment in a double-blind randomized placebo-controlled study. We used a
within-subject design to study 35 female PTSD patients who received oxytocin and placebo in a 2-week interval.
Furthermore, we performed a small pilot study to get an idea of the relation of the stress-modulated endogenous
oxytocin levels and heart rate - we correlated oxytocin serum levels with the heart rate of 10 healthy individuals before
and after exposure to the Trier Social Stress Test (TSST).
Results: Intranasal oxytocin treatment was followed by a reduction of provoked total PTSD symptoms, in particular of
avoidance, and by an elevation in baseline and maximum heart rate together with a drop in the pre-ejection period, a
marker for sympathetic cardiac control. Furthermore, we found a positive correlation between endogenous oxytocin
levels and heart rate both before and after TSST challenge in healthy control subjects.
Conclusions: This study provides the first evidence that oxytocin treatment reduces the intensity of provoked PTSD
symptoms in female PTSD patients. The small size of both samples and the heterogeneity of the patient sample restrict
the generalizability of our findings. Future studies have to explore the gender dependency and the tolerability of the
oxytocin-mediated increase in heart rate.
This randomized controlled trial was retrospectively registered at the German Trials Register (DRKS00009399) on the 02
October 2015.
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Background
For decades, oxytocin has been used for the induction of
labor and prevention of postpartum hemorrhage [1]. In
recent years there has been increasing evidence that this
nonapeptide, which is synthesized in the hypothalamus,
might also be suitable for the treatment of psychiatric
disorders such as schizophrenia, autism, major depres-
sion, anxiety disorders [2] and post-traumatic stress
disorder (PTSD) [3]. In response to a variety of stimuli
such as suckling, parturition and stress, oxytocin is
released from the posterior pituitary into the blood-
stream and transported to its effector organs such as the
heart, the kidney and the brain [4]. Oxytocin acts
through the oxytocin receptor (OTX) [4], which is
expressed for instance in the amygdala and the anterior
cingulate cortex [5], two brain regions known to be in-
volved in the pathobiology of stress-related psychiatric
diseases such as PTSD [3]. There is an unmet need for
the development of drugs specifically tackling the core
symptoms of this trauma spectrum disorder [6], which
are hyperarousal, aversive re-experiencing, emotional
numbing and avoidance anxiety, because 20–30% of
PTSD patients do not respond at all to treatment with
the current gold standard of PTSD drug therapy, the
serotonin re-uptake inhibitors [7]. Among other
neuropeptides such as neuropeptide S (NPS) [8] and
neuropeptide Y (NPY) [8, 9], oxytocin has been repeat-
edly suggested to be effective in PTSD treatment [3, 9].
In 1993, Pitman and colleagues were the first to test
the efficacy of oxytocin versus placebo in PTSD [10].
They applied either 20 IU oxytocin, vasopressin or pla-
cebo to male PTSD combat veterans before their expos-
ure to various tasks (inter alia to combat audiovisual
stimuli) and compared the heart rate (HR), electromyog-
raphy, skin conductance and psychological responses be-
tween the three groups [10]. The only differences they
noted were “a significantly higher baseline SC [skin con-
ductance] level and a trend toward a higher baseline
EMG [electromyographic]” response in the oxytocin
group. Seventeen years later, another study, published
hitherto as a poster abstract only, revealed more promis-
ing results because the authors reported a significant ef-
fect of a single dose of 24 IU oxytocin on non-provoked
PTSD symptoms, in particular on the intensity of recur-
rent thoughts about the traumatic event and on the de-
sire for social interaction [11, 12]. Accordingly, Olff and
colleagues reported that oxytocin treatment decreased
amygdalar reactivity toward emotional faces in PTSD
patients [13] and Acheson and colleagues demonstrated
that 24 IU of intranasal oxytocin facilitated fear extinc-
tion in healthy human subjects [14]. Currently, the effi-
cacy of oxytocin on secondary prevention of PTSD is
evaluated in a double-blind randomized placebo-
controlled trial [15]. Intranasal treatment with 40 IU
oxytocin was found to intensify trauma-script-induced
re-experiencing symptoms in recently traumatized
healthy subjects [16] but to attenuate stress reactivity,
including the cortisol response, in patients with border-
line personality disorder [17], a psychiatric disease
known to have a high comorbidity and symptom overlap
with PTSD [18]. In addition, two other studies have
demonstrated that intranasal oxytocin reduces stress-
induced cortisol levels [19, 20], thereby emphasizing the
interrelationship of the oxytocin system and the
hypothalamic-pituitary-adrenal axis, which, in turn, has
been repeatedly shown to play a central role in PTSD [6,
21].
There are, to the best of our knowledge, only two
studies thus far that have analyzed the efficacy of oxyto-
cin on PTSD symptom intensity in PTSD patients,
among them one symptom provocation study that was
performed in a cohort of male veterans [10]. This moti-
vated us to perform the first study analyzing the efficacy
of oxytocin on provoked PTSD symptoms in female
PTSD patients. Testing a female PTSD patient cohort is
of particular relevance because gender differences in the
effects of oxytocin have been repeatedly reported [22,
23] and because PTSD is more prevalent in women. Be-
sides analyzing the influence of intranasal oxytocin on
PTSD symptoms, we put particular emphasis on evaluat-
ing its effects on cardiac control, because, apart from
oxytocin’s undisputed role in cardiovascular regulation
[24], its effects on HR remain unclear: on the one hand,
oxytocin has been reported to reduce HR [24]; on the
other hand, there are numerous publications reporting
that oxytocin treatment, especially oxytocin bolus appli-
cation, can lead to tachycardia [25, 26]. Accordingly,
there are studies showing that oxytocin increases HR in
mice [27, 28], rats [29] and dogs [30]. In contrast, Pit-
man and colleagues found no changes in HR in male
PTSD veterans, neither at baseline nor in response to
combat audiovisual stimulus [10]. In consequence of
these discrepancies, Novartis reports that “cardiovascular
changes including tachycardia and bradycardia can be
common” (p.1115) in response to oxytocin treatment
[31]. There is one study that nicely demonstrated the
Sack et al. BMC Medicine  (2017) 15:40 Page 2 of 11
influence of individual psychological factors on
oxytocin-mediated cardiac control by showing that
higher levels of loneliness were associated with reduced
parasympathetic cardiac reactivity to intranasal oxytocin
[32]. In the latter study, oxytocin significantly increased
overall autonomic cardiac control because it elevated
high frequency heart rate variability (HRV) and de-
creased the pre-ejection period (PEP), a well-known in-
dicator of sympathetic cardiac control. Because PTSD
dramatically increases the risk for cardiovascular mortal-
ity [33], it is of utmost importance to study the influence
of potential PTSD drugs on cardiac parameters. In the
study presented here, we analyzed, in addition to assessing
the psychological response, the respiration rate and several
cardiac parameters, namely HR, HRV and PEP, not only at
baseline but also after symptom provocation.
Methods
Demographic and clinical characteristics of the PTSD
patient cohort (trauma-script challenge experiment)
Between November 2010 and December 2012, we re-
cruited 35 adult female Caucasian patients with full
PTSD from consecutive outpatients attending the Clinic
for Psychosomatic Medicine and Psychotherapy of the
Technical University of Munich (TUM). At the time of
analysis, patients had to fulfill the diagnostic criteria for
full PTSD syndrome according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition
(DSM-IV), had to be between 18 and 70 years old, and
had to have sufficient knowledge of the German lan-
guage to complete the questionnaires. Patients treated
with beta-adrenoreceptor antagonists or other cardiovas-
cular active drugs were excluded from the study.
Additional exclusion criteria were lifetime history of
psychosis, bipolar disorder, active substance abuse or
suicidal ideation.
Demographic and clinical characteristics of the control
subject cohort (Trier Social Stress Test experiment)
The 10 healthy adult Caucasian women assessed here
for their endogenous oxytocin plasma levels, cortisol
serum levels, HR and subjective stress response consti-
tute a subsample of a previously published cohort [21]
that was subjected to the Trier Social Stress Test
(TSST). Thus, this small cohort of healthy subjects was
not included in the randomized clinical trial (RCT) but
served as an additional experiment. They were recruited
in the Trauma Outpatient Clinic of the Max Planck In-
stitute of Psychiatry in Munich by advertisement and
were free from trauma history, from any medication and
from any type of psychopathology in their lifetime as de-
tailed previously [21]. As published [21], participants of
this TSST study had to fill in various questionnaires at
various time-points before and after the TSST challenge.
Baseline psychological assessment
Trauma-script challenge experiment: After written in-
formed consent was obtained, all patients were asked to
answer standardized demographic questions. PTSD
symptoms were assessed with the authorized German
translation [34] of the Structured Clinical Interview for
DSM-IV (SKID-PTSD) and psychiatric comorbidities
with the International Classification of Diseases and Re-
lated Health Problems, Tenth Revision (ICD-10) check-
lists [35]. The authorized German translation of the
Structured Clinical Interview for DSM-IV Dissociative
Disorders (SCID-D) [36], which comprises five numer-
ical subscales and has an overall score of 20, was used to
assess the presence of a dissociative disease. A SCID-D
total score of ≥10 reflects a complex and severe dissocia-
tive disorder. In addition, self-report data were obtained
to evaluate the trauma-related symptom load with the
German version of the 15-item self-report Impact of
Event Scale (IES) [37] and for dissociative symptoms
with the Dissociative Experiences Scale (DES) [38].
TSST challenge experiment: As reported in detail pre-
viously [21], medically healthy participants without any
present or lifetime psychopathology and without any
trauma exposure were identified with the Munich
Composite International Diagnostic Interview (M-CIDI)
[39] after written informed consent had been obtained.
Oxytocin treatment and trauma-script challenge of
patients
An overview of both challenge paradigms, that is, of the
trauma-script challenge and the TSST challenge para-
digm, are depicted in Fig. 1. The study protocol of this
RCT (trial registration number: DRKS00009399) is avail-
able upon request. The RCT followed the CONSORT
guidelines [40]; the CONSORT diagram is provided in
Additional file 1: Figure S1 and the CONSORT checklist
in Additional file 1: Table S1.
Not later than 14 days after baseline assessments,
PTSD patients were subjected to the following challenge
protocol: 45 min before start of the stress experiment,
PTSD patients received, in a randomized order, either
24 IU oxytocin (Syntocinon®, Novartis, Brazil) or vehicle
(placebo) intranasally. The placebo included all of the
same ingredients as the oxytocin intranasal spray except
oxytocin – inter alia purified water, NaCl and preserva-
tives. Then, the respiratory frequency (RESP) and the
cardiovascular parameters HR, HRV and PEP were
assessed at baseline, that is, directly before the trauma-
script challenge (from minute 46 to minute 50) and
again during trauma-script exposure (from minute 51 to
minute 53). From minute 53 on, the psychological reac-
tion to stress exposure was assessed with the Responses
to Script-Driven Imagery Scale (RSDI) [41]. All patients
served as their own controls and were thus assessed
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twice, that is, they received, in a 1-week interval, oxyto-
cin in one experiment and placebo in the other (within-
subject design) in a double-blind randomized order.
Patients were randomized using a predefined computer-
based block-wise randomization plan performed by a
staff member from another institute (the TUM data cen-
ter). Both the investigators and the patients were blinded
to the intervention type until the end of the study. The
spray bottles containing either oxytocin or placebo were
labeled with a code number by a staff member not
otherwise involved in the study. We made every effort to
keep blinding integrity, however, we did not assess it.
The primary outcome variable was the efficacy of intra-
nasal oxytocin on PTSD symptoms provoked by trauma-
script exposure in female PTSD patients. There were no
important changes to methods after trial commence-
ment and no drop-outs.
Psychophysiological assessment upon trauma-script
challenge
The script-driven imagery procedure used here differed
from the standard approach [42] in that we employed a
script of 2 min rather than of 30 s, and we skipped the
imagery period at the end of the script [43]. The RSDI
[41] was presented to patients as a self-report question-
naire that they filled in in the presence of an investiga-
tor. The 11-item RSDI was developed to provide a brief
and face valid measure of state PTSD and dissociative
symptoms elicited by script-driven imagery, a widely
used symptom provocation method in PTSD research.
The RSDI measures state re-experiencing, avoidance and
dissociative symptoms evoked by script-driven trauma
imagery. The predicted three-factor solution is sup-
ported by confirmatory factor analyses, including tests
for sample invariance across measurement and struc-
tural models in three different samples, with the fully
constrained model exhibiting good model fit. The
response format is a 7-point Likert scale. In the current
study, the RSDI was administered in a questionnaire
form in the presence of the investigator to ensure
comprehension of the directions and to allow partici-
pants to ask for clarification about particular items.
Further details on the procedure and devices used for
assessment of cardiovascular parameters and of RESP
are given in Additional file 1: Supplemental Methods.
Trier Social Stress Test of healthy participants
The TSST challenge experiment was not part of the
RCT but an additional experiment. As explained above,
the healthy subjects presented here constitute a sub-
sample of a previously published cohort [21]. Here, we
assessed, for the first time, their oxytocin serum levels at
baseline and immediately after exposure to the TSST, a
standardized social stress experiment [44], the protocol
of which we described in detail before [21]. Collection of
blood samples and assessment of HR was also described
previously [21] and accomplished 30 min before (base-
line) and immediately after the TSST, that is, at
1:30 p.m. and at 2:10 p.m. Further details on the proced-
ure of sample processing are given in Additional file 1:
Supplemental Methods. We extracted raw HR data for
Fig. 1 Graphical overview of study design. For further explanations, see “Methods”. The heart symbol represents an assessment of cardiac parameters
and respiratory frequency. diss. dissociative symptoms, Abbreviations: PTSD post-traumatic stress disorder, RSDI Responses to Script-Driven Imagery Scale,
TSST Trier Social Stress Test
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these 10 individuals from our previous publication [21]
to correlate with their oxytocin serum levels. As we
explained previously [21], subjective stress perception
was assessed with the Visual Analogue Scale.
Enzyme-linked immunosorbent assay analysis of oxytocin
serum levels
We used 50 μl of serum from healthy control partici-
pants to assess oxytocin serum levels using a commer-
cially available ELISA kit (USCN Life Sciences, Wuhan,
China; range of detection: 2.35–1000 pg/ml; sensitivity
4.45 pg/ml) as described by the manufacturer. Samples
were assessed in duplicate. Further details on oxytocin
analysis are given in Additional file 1: Supplemental
Methods.
Determination of serum cortisol
As we described in further detail previously [21], the
concentration of cortisol levels in the serum of healthy
subjects was determined with an electrochemilumines-
cence immunoassay employing the modular analytics
EVO analyzer (Roche, Mannheim, Germany).
Statistics
Data were analyzed using SPSS statistical package ver-
sion 22. All data were checked for normal distribution.
Trauma-script challenge: Assuming an effect size of
0.5, we calculated a sample size of 34 prior to the study
[Input: tail(s) = 2; effect size dz = 0.5; α error probability =
0.05; power (1 − β error probability) = 0.80. Output: non-
centrality parameter δ = 2.9154759; critical t = 2.0345153;
degrees of freedom= 33; total sample size = 34; actual
power = 0.8077775]. Mean values of all psychophysiological
data recorded at baseline (during the last 60 s of the 5 min
baseline protocol) and when listening to the audiotaped
trauma script (first 60 s of the challenge protocol) were cal-
culated. To evaluate physiological data and subjective reac-
tions to the trauma script (RSDI questionnaire), we
performed a linear mixed model analysis (LMM) with
placebo/oxytocin as the repeated factor (see “Results” and
Additional file 1: Table S2). In case of a non-normal distri-
bution of the data, non-parametric tests (Mann–Whitney
tests) were conducted. Since the latter results did not differ
from the parametric analysis, we report only the results
from the LMM. All patients included in this RCT were also
included in analyses.
TSST challenge: According to the results of the
Kolmogorov–Smirnov test, all data were normally dis-
tributed. Differences in oxytocin serum levels, HR, corti-
sol and subjectively perceived stress before and after
stress exposure were calculated with separate one-way
ANOVAs (Fig. 2a, b and Additional file 1: Figure S2).
The relationship between oxytocin levels and HR before
and after TSST exposure was analyzed with Pearson’s
correlation coefficient (Fig. 2c, d). The effects of control
variables (age, body mass index (BMI), ovarian cycle of
healthy participants), all assessed as detailed previously
[21], were calculated with partial correlations.
Results
Demographics and clinical characteristics of the PTSD
patient sample
Demographic and clinical characteristics of this patient
cohort are summarized in Table 1. The mean age of the
35 white Caucasian female PTSD patients included was
39.8 years (range 22–70 years). Seventeen of them (49%)
had a university-entrance diploma (German: Abitur), ten
(29%) had a General Certificate of Secondary Education
(German: Realschulabschluss) and eight (22%) had a
Lower General Certificate of Secondary Education
(German: Hauptschulabschluss). Twenty patients (57%)
were in a relationship, 15 (43%) were not. Twenty-one of
the study participants (60%) were not married, eight
(23%) were married, five (14%) were divorced and one
(3%) was widowed. Twelve participants (34%) had
children. Eight patients (23%) were full-time employed,
eight (23%) were part-time employed, 14 (40%) were
retired and five (14%) were unemployed.
Eighteen patients (51.4%) received serotonin reuptake
inhibitors, eleven patients (31.4%) were treated with an-
tidepressants, nine patients (25.7%) with neuroleptics,
five patients (14.3%) with benzodiazepines, twelve pa-
tients (34.3%) underwent combined pharmacotherapy
and ten patients (28,5%) received no medication. All
patients fulfilled DSM-IV diagnostic criteria for PTSD,
and PTSD symptoms were their major complaint. The
mean age at first traumatization was 7.7 years (range 2–
22 years). Most patients (n = 26, 74%) suffered from early
relational trauma. With regards trauma history, 17
(48.6%) were exposed to sexual violence by a family
member, six (17.1%) to non-sexual violence by a family
member, four (11.4%) to an accident, three (8.6%) to or-
ganized sexual violence, two (5.7%) to sexual violence by
a stranger, two (5.7%) to non-sexual violence by a stran-
ger and one (2.9%) to a natural disaster. Thus, 22
(62.9%) of our patients reported a sexual trauma.
Because we observed that severe distress and even dis-
sociative symptoms can be provoked by the assessment
of sexual functions in sexually traumatized patients, we
dispensed with it. With regards comorbidities, 19 partic-
ipants (54.3%) were diagnosed with a dissociative
disorder. Accordingly, the mean SCID-D score of the
cohort was >10, namely 12.7 (Table 1). Moreover, 23
patients (65.7%) had a current depressive disorder, 11
(31.4%) an anxiety disorder, ten (28.6%) a somatoform
disorder and six (17.1%) a borderline-personality
disorder.
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Intranasal oxytocin reduces provoked PTSD symptoms
First, we analyzed the efficacy of oxytocin treatment on
PTSD symptoms triggered by trauma-script exposure.
Provoked PTSD symptoms were assessed with the RSDI
questionnaire that allows quantification of avoidance, re-
experiencing and dissociation symptoms provoked by
exposure to an audiotaped individual trauma script [41].
We found that the total RSDI score was significantly
reduced in oxytocin-treated patients (Table 2, p = 0.012).
Thus, intranasal oxytocin treatment significantly attenu-
ated PTSD symptoms triggered by trauma-script
exposure. Analysis of the three different symptom clusters
revealed that the oxytocin-mediated reduction in dissocia-
tive and re-experiencing symptoms was not significant
(Table 2). However, oxytocin treatment attenuated avoid-
ance – at least with a trend for statistical significance
(Table 2, p = 0.093). Comparative analysis of the psycho-
physiological variables of the first and the second experi-
ment revealed no adaptation effects.
Intranasal oxytocin exerts positive chronotropic effects
Data presented in Additional file 1: Table S2 are also
presented in Table 2; however, in contrast to Table 2,
Additional file 1: Table S2 allows for immediate
judgment of the statistical significance of the effects of
oxytocin treatment on baseline parameters: intranasal
oxytocin treatment elicited a significant elevation in the
baseline HR of PTSD patients (Additional file 1: Table S2,
p = 0.02) but no significant differences in the other psy-
chophysiological variables tested at baseline (HRV, PEP,
RESP) (Additional file 1: Table S2). The positive chrono-
tropic effect of oxytocin also became apparent during
trauma-script exposure because oxytocin-treated patients
exhibited a significantly higher maximum HR (Table 2,
p = 0.020) and, in addition, a trend-wise increase in
HR after trauma-script challenge (Table 2, p = 0.59).
The latter finding indicates that oxytocin treatment
promotes the stress-induced increase in HR in PTSD
patients.
Because reports on the influence of oxytocin on the
regulation of HR are hitherto inconsistent, we analyzed
the HR and endogenous oxytocin levels in another
cohort, namely a small cohort of healthy women sub-
jected to a different stressor, the standardized social
stressor TSST. This cohort constitutes a subsample of a
previously published sample [21]. The mean age of the
10 white Caucasian healthy non-traumatized unmedi-
cated participants was 36.08 years (SD = 8.56, range 22–
Fig. 2 Oxytocin serum levels correlate positively with heart rate both before and after social stress exposure. Ten healthy female participants were
subjected to the Trier Social stress Test (TSST). Their serum oxytocin levels and heart rate were assessed at baseline (30 min before) and
immediately after the TSST challenge. a, b Differences in oxytocin serum levels and heart rate before and after stress induction were calculated
with separate one-way ANOVAs. c, d Correlation analyses were performed using Pearson’s correlation coefficient. All data are presented as mean
± standard error of the mean. * p ≤ 0.05; *** p≤ 0.001. For further statistical details, see main text
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51 years). According to the participants’ self-reports on
their first day of the last menstrual period and the aver-
age ovarian cycle duration, six participants were in the
follicular phase, three in the luteal phase and one reported
menopause. Their BMI values were all normal (mean =
23.54 kg/m2, SD = 3.13, range 18.07–28.34 kg/m2).
As expected from the already published analysis of the
total sample [21], TSST exposure of the healthy control
subjects tested here induced a substantial increase in
their serum cortisol levels (Additional file 1: Figure
S2A, F(1, 19) = 24.89, p < 0.001) and in the intensity
of their subjectively perceived stress (Additional file 1:
Figure S2B, (F(1, 19) = 37.40, p < 0.001). In contrast,
the increase in HR and in oxytocin serum levels was
not statistically significant (Fig. 2a, b). However, we
found a strong and significant positive correlation be-
tween the two parameters both before and after TSST
challenge. We cannot exclude that this notably strong
correlation results from a methodological artifact
driven by the small sample size; however, it did not change
significantly after controlling for age (before stress: r = 0.93,
p < 0.001; after stress: r = 0.71, p = 0.031), BMI (before
stress: r = 0.91, p = 0.001; after stress: r = 0.70, p = 0.03) and
ovarian cycle (before stress: r = 0.90, p = 0.001; after stress:
r = 0.67, p = 0.048) (Fig. 2c, d). In summary, our data
provide strong evidence that oxytocin exerts positive
chronotropic effects in women.
Evidence for sympathomimetic effects of intranasal
oxytocin
In order to get an idea of the influence of intranasal oxy-
tocin on the sympathetic and parasympathetic nervous
system (SNS, PNS), we assessed additional cardiac pa-
rameters. Our finding of a reduction in PEP, a well-
known marker of sympathetic cardiac control [32], in
oxytocin-treated patients (Table 2, p = 0.007) supports
the hypothesis that the oxytocin-elicited elevation in HR
might be mediated through SNS activation – at least
under conditions of stress. In contrast, we found no
Table 2 Effects of oxytocin versus placebo on cardiac parameters and trauma-related psychopathological symptoms at baseline and
in response to trauma-script challenge
Placebo Oxytocin Repeated effects comparison (LMM) Effect size
baseline Trauma script baseline Trauma script
mean (SD) mean (SD) mean (SD) mean (SD) F (DF) p-value Cohen’s d (95% CI)
HR (bpm) 75.9 (9.6) 82.1 (11.4) 77.9 (8.9) 87.2 (15.0) 3.0 (34) 0.059t 0.291 (−0.00–0.50)
HR max (bpm) 88.1 (12.6) 93.8 (15.2) 12.8 (34) 0.020* 0.605 (0.34–0.87)
HRV (ms) 3.15 (.65) 2.91 (.79) 3.05 (.79) 2.79 (.85) 0.26 (34) 0.67 0.088 (−0.15–0.33)
PEP (ms) 76.0 (12.2) 74.2 (12.9) 74.4 (13.6) 70.0 (17.7) 8.8 (33) 0.007** 0.515 (0.26–0.77)
RESP (bpm) 15.6 (3.0) 17.1 (3.8) 15.1 (3.1) 16.7 (4.2) 0.01 (34) 0.95 0.001 (−0.39–0.41)
RSDI-total 2.87 (1.1) 2.44 (.90) 7.1 (34) 0.012* 0.459 (0.13–0.79)
RSDI-Re-experiencing 3.74 (1.3) 3.30 (1.2) 2.2 (34) 0.15 0.342 (−0.11–0.70)
RSDI-Avoidance 2.52 (1.8) 1.92 (1.4) 3.0 (34) 0.093t 0.289 (−0.14–0.72)
RSDI-Dissociation 2.26 (1.8) 1.96 (1.4) 1.2 (34) 0.26 0.195 (−0.13–0.52)
Abbreviations: bpm beats per minute, CI confidence interval. HR heart rate, HR max heart rate maximum during trauma-script challenge, HRV heart rate variability
(logarithmically transformed), LMM linear mixed model analysis, PEP pre-ejection period, RESP respiration rate (breaths per minute), RSDI Response to Script-Driven
Imagery Scale (for citation, see main text), SD standard deviation. Symbols: t ≤ 0.1; *p ≤ 0.05; **p ≤ 0.01. All effects of physiological data have been controlled for
influences of baseline values
Table 1 Sociodemographic and clinical characteristics of the
post-traumatic stress disorder patient sample subjected to the
trauma-script challenge
Characteristic Mean (SD) or N (%)
Age (years) 39.8 (11.2)
Age (years) at first traumatization 7.7. (4.8)
Female sex 35 (100%)
Education
< 10 years 8 (22%)
10–12 years 10 (29%)






Multiple traumatization 29 (83%)
Psychological variables
SCID-D score 12.1 (4.7)
DES 23.4 (15.7)
IES 46.6 (14.7)
Abbreviations: DES Dissociative Experiences Scale, IES Impact of Event Scale, SCID-D
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
Disorders, 4th edition – Dissociative Disorders. For citations, see main article
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evidence that oxytocin treatment influenced the para-
sympathetic tone because the HRV did not differ be-
tween oxytocin- and placebo-treated patients – neither
at baseline (Additional file 1: Table S2) nor after the
trauma-script challenge (Table 2). Taken together, intra-
nasal oxytocin treatment attenuates the intensity of
provoked PTSD symptoms (Table 2) despite exerting
sympathomimetic and positive chronotropic effects
(Additional file 1: Table S2, Table 2). PTSD patients
analyzed here did not report unintended effects. Accord-
ingly, besides the positive chronotropic effect of oxytocin
treatment, we did not observe any other unintended
effect or harm of treatment.
Discussion
This is the first study assessing the effects of oxytocin
on the intensity of provoked PTSD symptoms in female
PTSD patients and, to the best of our knowledge, the
second symptom provocation study analyzing the effi-
cacy of oxytocin in PTSD patients ever. Taken together,
we show here for the first time that intranasal oxytocin
reduces the trauma script-provoked expression of PTSD
symptoms, in particular avoidance (Table 2). Further-
more, the oxytocin-mediated increase in HR (Additional
file 1: Table S2; placebo baseline: 75.9 bpm (SD 9.6);
oxytocin challenge: 77.9 bpm (SD 8.9); p = 0.020) gets
slightly more pronounced in response to stress (Table 2;
oxytocin baseline: 82.1 bpm (SD 11.4); oxytocin chal-
lenge: 87.2 bpm (SD 15.0); p = 0.095). The here-observed
immediate influence of intranasal oxytocin on psycho-
pathology and hence on brain function is supported by
primate studies showing that intranasal oxytocin, such
as other intranasally administered anxiolytic neuropep-
tides like NPS [45], are able to reach the cerebrospinal
fluid [46, 47] and thus, assumingly, also the brain. In
addition, our experiments revealed that oxytocin signifi-
cantly increased the HR in female PTSD patients both at
baseline (Additional file 1: Table S2) and upon trauma-
script exposure (Table 2), helping to clarify the hitherto
still not fully elucidated influence of oxytocin on HR [10,
24–26, 31, 32]. Our finding of a positive chronotropic ef-
fect of oxytocin is supported by the positive correlation
of endogenous oxytocin levels and HR both before
(Fig. 2c) and after (Fig. 2d) TSST challenge in a cohort
of healthy subjects.
In contrast to our findings (Fig. 2a, b), de Jong and
colleagues found a significant increase in salivary oxytocin
levels of healthy subjects in response to TSST exposure
[48]. However, from the fact that a correlation of salivary
and plasma oxytocin levels was absent in another study on
healthy individuals [49], we conclude that our results do
not contradict those of de Jong and colleagues. Because
there is some controversy on the measurement of oxyto-
cin in the literature, in particular on the determination of
oxytocin in unextracted plasma samples [50, 51], we de-
cided to determine oxytocin levels in serum samples and
to use a hitherto uncriticized ELISA kit, although it has
not yet been extensively validated. In spite of this, the oxy-
tocin levels we report here are higher than those obtained
by others with extracted samples. However, the facts that
the levels were still much lower than those documented
with the criticized assays and, moreover, showed a positive
association with stress (Fig. 2c, d), as expected from the
extrapolation of previously published data [52], strongly
suggest that a potential sample-matrix interference, if
existent at all, did not corrupt our results.
Because we found intranasal oxytocin to enhance
the challenge-mediated decrease in PEP but not
oxytocin-mediated modulation of HRV (Table 2), a
known measure for parasympathetic activity [53], we
hypothesize that the positive chronotropic effect of
oxytocin observed here occurs through an oxytocin-
elicited activation of the SNS rather than through an
oxytocin-mediated dampening of the PNS. Our
results on the influence of oxytocin on HR and PEP
in PTSD patients are in full accordance with those
of another research group that found intranasal oxy-
tocin to increase the HR and to decrease PEP in
healthy individuals [32]. However, in contrast to the
latter publication, we did not detect a significant
increase in HRV in our cohort (Table 2). This differ-
ence might have been caused by differences in study
design, but could also indicate that oxytocin-
mediated activation of the PNS might be altered in
PTSD patients. This supposition is supported by
previous studies showing that, besides the SNS [54],
the PNS also plays a role in PTSD. For example,
parasympathetic activity was found to influence basal
HR in PTSD patients [55] and to be lower in Cro-
atian combat veterans [56]. In contrast, it is well
accepted that the SNS is overactive in PTSD [54].
Of note, only little of the intranasally administered
oxytocin reaches the brain. Accordingly, it has been
suggested that the central nervous effects of oxytocin
might be a consequence of its peripheral actions
[57], such as its influence on cardiac function.
Gender differences in oxytocin effects have been re-
peatedly described [22, 23] and might, besides a variety
of other factors, contribute to the partial differences be-
tween our study and that of Norman and colleagues
[32], as well as of Pitman and colleagues [42], who, in
contrast to us, did not find an effect of intranasal oxy-
tocin on provoked PTSD symptoms in male veterans.
In recent years, oxytocin has been repeatedly proposed
as an effective novel drug treatment for PTSD [3, 58],
but, to the best of our knowledge, there have only been
two prior studies that assessed the effects of oxytocin
treatment on the intensity of PTSD symptoms in
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humans [10, 12]. Thus, our study contributes signifi-
cantly to our understanding of the therapeutic potential
of oxytocin in PTSD. The findings of our clinical trial
support the use of oxytocin in PTSD treatment, in par-
ticular for medication-enhanced exposure therapy.
Interestingly, separate analysis of the different PTSD
symptoms revealed that avoidance was the only PTSD
symptom to be reduced, at least with a trend for statis-
tical significance, by oxytocin treatment (Table 2). Simi-
larly, previous studies found that oxytocin attenuated
avoidance behavior in rodents [59, 60]. Because our ex-
periments revealed that oxytocin treatment trend-wise
reduced avoidance behavior despite enhancing HR and
sympathetic cardiac control (Table 2), we speculate that
PTSD-associated avoidance behavior is not causally
linked to PTSD-associated SNS overactivity [54].
The relatively small sample size of both samples and the
heterogeneity of the patient sample (e.g., the broad range
of age, differences in pharmacotherapy and in trauma
types) as well as the facts that we analyzed women only
and did not include the ovarian cycle phase as a covariate
in the analysis of the patient sample limit the
generalizability of our results. In a future study we aim to
address the question of whether the therapeutic effect of
intranasal oxytocin on provoked PTSD symptoms
observed here is gender dependent. Moreover, even
though we did not observe any unintended effects of oxy-
tocin treatment in addition to its positive chronotropic
effects, there is still the possibility of unknown unintended
long-term consequences. Future experiments will have to
clarify whether the beneficial effects of oxytocin in PTSD
treatment described here (Table 2) outweigh the fact that
oxytocin stimulates both HR and sympathetic activity
(Additional file 1: Tables S2, S3 and [32]), which are both
known to be already enhanced in PTSD [54].
Conclusions
This study provides the first evidence that oxytocin
treatment reduces the intensity of provoked PTSD
symptoms in female PTSD patients therewith suggesting
intranasal oxytocin as a potential novel treatment option
for PTSD - in particular for medication-enhanced psy-
chotherapy. Future studies have to explore the gender
dependency and the tolerability of the oxytocin-
mediated increase in SNS activity and in heart rate.
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